GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » PS Ratio

ZLAB (Zai Lab) PS Ratio : 9.11 (As of Oct. 31, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zai Lab PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zai Lab's share price is $30.223. Zai Lab's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $3.32. Hence, Zai Lab's PS Ratio for today is 9.11.

The historical rank and industry rank for Zai Lab's PS Ratio or its related term are showing as below:

ZLAB' s PS Ratio Range Over the Past 10 Years
Min: 4.69   Med: 58.65   Max: 18440
Current: 9.26

During the past 9 years, Zai Lab's highest PS Ratio was 18440.00. The lowest was 4.69. And the median was 58.65.

ZLAB's PS Ratio is ranked worse than
50.25% of 1001 companies
in the Biotechnology industry
Industry Median: 9.34 vs ZLAB: 9.26

Zai Lab's Revenue per Sharefor the three months ended in Jun. 2024 was $1.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $3.32.

Warning Sign:

Zai Lab Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Zai Lab was 26.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was 63.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 254.30% per year.

During the past 9 years, Zai Lab's highest 3-Year average Revenue per Share Growth Rate was 818.90% per year. The lowest was 63.60% per year. And the median was 123.20% per year.

Back to Basics: PS Ratio


Zai Lab PS Ratio Historical Data

The historical data trend for Zai Lab's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab PS Ratio Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only 205.89 214.83 40.50 13.67 9.90

Zai Lab Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.59 8.89 9.90 5.33 5.22

Competitive Comparison of Zai Lab's PS Ratio

For the Biotechnology subindustry, Zai Lab's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's PS Ratio distribution charts can be found below:

* The bar in red indicates where Zai Lab's PS Ratio falls into.



Zai Lab PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Zai Lab's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=30.223/3.319
=9.11

Zai Lab's Share Price of today is $30.223.
Zai Lab's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.32.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Zai Lab  (NAS:ZLAB) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Zai Lab PS Ratio Related Terms

Thank you for viewing the detailed overview of Zai Lab's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Executives
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Edmondson Frazor Titus Iii officer: Chief Legal Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Joshua L Smiley officer: Chief Operating Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Yajing Chen officer: Chief Financial Officer 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142
Rafael Amado officer: See Remarks 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ying Du director, officer: Chairwoman & CEO C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210
Harald Reinhart officer: Chief Medical Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Peter Wirth director 37 HANCOCK STREET, BOSTON MA 02114
John D Diekman director C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Tao Fu director, officer: President & COO 3175 HANOVER STREET, PALO ALTO CA 94304
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Cho William Ki Chul officer: Chief Financial Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Kai-xian Chen director 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210